Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 17, 2008

Tethys Purchases Lipomics Technologies to Enhance Capabilities in Diagnostic Development

  • Tethys Bioscience has taken over Lipomics Technologies. The transaction brings together Lipomics' metabolite profiling technology and lipid biology expertise with Tethys' protein biomarker analysis capabilities.

    Tethys launched its first diagnostic earlier this year, called the PreDx™ Diabetes Risk Test. The firm is now working on tools to predict a person's likelihood of experiencing an osteoporotic bone fracture or a major cardiac event.

    “We believe that the best solutions for predicting and thereby preventing a range of chronic conditions will come from the thoughtful integration of multiple types of biomarkers including proteins and metabolites,” says Mickey Urdea, Tethys' founder, chairman, and CEO.
    The acquisition was completed today, and integration of both entities is under way, Tethys reports. All 30 employees of Lipomics will become part of Tethys. The Lipomics facility will continue its activities as Tethys West Sacramento.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »